Heparin-induced thrombocytopenia: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
{{Heparin-induced thrombocytopenia}} | |||
{ | |||
{{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}}, [[Priyamvada Singh|Priyamvada Singh, M.B.B.S.]] [mailto:psingh13579@gmail.com], Aric C. Hall, M.D., [mailto:achall@bidmc.harvard.edu] | {{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}}, [[Priyamvada Singh|Priyamvada Singh, M.B.B.S.]] [mailto:psingh13579@gmail.com], Aric C. Hall, M.D., [mailto:achall@bidmc.harvard.edu] | ||
Revision as of 21:05, 9 January 2014
Heparin-induced thrombocytopenia |
Differentiating Heparin-induced thrombocytopenia from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Heparin-induced thrombocytopenia On the Web |
American Roentgen Ray Society Images of Heparin-induced thrombocytopenia |
Directions to Hospitals Treating Heparin-induced thrombocytopenia |
Risk calculators and risk factors for Heparin-induced thrombocytopenia |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2], Priyamvada Singh, M.B.B.S. [3], Aric C. Hall, M.D., [4]
Overview
Pathophysiology
Epidemiology and Demographics
Causes
Classification
Risk Factors
Differential diagnosis
Diagnosis
History and symptoms
Lab tests
Treatment
Medical therapy
See also
Heparin-associated thrombocytopenia
Heparin-binding EGF-like growth factor